Biological Activity Cagrilintide and semaglutide, when co-administered, produce synergistic reductions in bodyweight (up to ~1517% over 2032 weeks in clinical trials) and significant improvements in glycemic parameters, including HbA1c and fasting glucose
Unlike mass-produced, commercially available drugs, compounded medications are designed to meet unique health needs that may not be addressed by FDA-approved products alone
It also reduces appetite and food intake via effects on the brain
Patients should be counseled on maintaining adequate hydration and balanced nutrition despite reduced appetite
Not every patient progresses through titration at the same pace, and clinicians may adjust the schedule depending on tolerance and response to treatment
But what is Semaglutide, and why is it garnering so much attention